Used in clinical research for the treatment of acute leukemia, particularly acute myeloid leukemia (AML). It acts as a potent and selective inhibitor of the lysine-specific histone demethylase LSD1 (KDM1A), which plays a key role in regulating gene expression involved in cell differentiation and proliferation. By inhibiting LSD1, the compound promotes differentiation of leukemic cells and reduces their growth. It has shown promise in early-phase trials, especially in combination with other agents like retinoic acid, to reactivate silenced genes and restore normal differentiation pathways in cancer cells. Development focuses on targeted epigenetic therapy with potentially fewer side effects than conventional chemotherapy.